Dr. Northfelt is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
5777 E. Mayo Boulevard
Phoenix, AZ 85050- Is this information wrong?
Summary
- Dr. Donald Northfelt is an oncologist in Scottsdale, AZ and is affiliated with Mayo Clinic Hospital and U. S. Public Health Service Phoenix Indian Medical Center. He received his medical degree from University of Minnesota Medical School and has been in practice 32 years. He specializes in breast cancer, general medical oncology, and hematologic disorders including coagulation disorders.
Education & Training
- University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 1988 - 1991
- UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 1985 - 1988
- University of Minnesota Medical SchoolClass of 1985
- California Institute of TechnologyMS, Geochemistry, 1978 - 1980
- University of MinnesotaBS, Geology, High Distinction, 1973 - 1978
Certifications & Licensure
- AZ State Medical License 2002 - 2025
- CA State Medical License 1986 - 2024
- CO State Medical License 2014 - 2019
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2008-2014
- Top Doctors:Arizona State Castle Connolly, 2013
- America's Top Doctors for Cancer Castle Connolly, 2007-2013
- Join now to see all
Clinical Trials
- CCI-779 in Treating Patients With Stage IIIB (With Pleural Effusion) or Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2004 Feb 01
- Paclitaxel Poliglumex and Capecitabine in Treating Patients With Metastatic Breast Cancer Start of enrollment: 2006 Feb 01
- Pharmacogenetics of Anastrozole in Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Stage I, Stage II, or Stage III Breast Cancer Start of enrollment: 2005 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- Testing Adaptive Therapy Protocols Using Gemcitabine and Capecitabine in a Preclinical Model of Endocrine-Resistant Breast Cancer.Seyedi, S., Teo, R., Foster, L., Saha, D., Anderson, K., Gatenby, R., Cisneros, L., Troan, B., Anderson, A., Maley, C., Mina, L., Northfelt, D., Shibata, D.> ;Cancers. 2024 Jan 6
- Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast Cancer.Kyalwazi, B., Yau, C., Campbell, M., Yoshimatsu, T., Chien, A., Wallace, A., Forero-Torres, A., Pusztai, L., Ellis, E., Albain, K., Blaes, A., Haley, B., Boughey, J., ...> ;JAMA Network Open. 2023 Dec 1
- Implications of a Supernumerary Nipple Breast Cancer in a BReast CAncer Sequence Variation Carrier: A Case Report.Will Sperduto, Ann McCullough, Donald Northfelt, Lisa McGee, Barbara Pockaj, Kristen Jogerst> ;Mayo Clinic Proceedings. Innovations, Quality & Outcomes. 2023 Oct 1
- Join now to see all
Journal Articles
- Phase 2 Trial of Paclitaxel Polyglumex with Capecitabine for Metastatic Breast CancerNorthfelt DW, Allred JB, Liu HS, Hobday TJ, Rodacker MW, Lyss AP, Fitch TR, Perez EA, American Journal Of Clinical Oncology-cancer Clinical Trials, 1/1/2014
- Clinical Utility of Gene Expression Profiling Data for Clinical Decision-Making regarding Adjuvant Therapy in Early Stage, Node-Negative Breast Cancer: A Case ReportSchuster SR, Pockaj BA, Bothe MR, David PS, Northfelt DW, J Pers Med, 1/1/2012
- Osteoporosis Prevention in Prostate Cancer Patients Receiving Androgen Ablation Therapy: Placebo-controlled Double-blind Study of Estradiol and Risedronate: N01C8Kearns AE, Northfelt DW, Dueck AC, Atherton PJ, Dakhil SR, Rowland KM Jr, Fuloria J, Flynn PJ, Dentchev T, Loprinzi CL, Support Care Cancer, 1/1/2010
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Transcriptome-wide Association of Mki67 Expression: Pre- And Post-neoadjuvant PaclitaxelMoyer AM, Kalari KR, Thompson KJ, Visscher DW, Suman VJ, Eckel-Passow J, Sicotte H, Hart SN, Sinnwell JP, Dockter TJ, Jones KN, Conners AL, Tang X, Yu J, Gao B, Mahone..., Lab Invest, 1/1/2014
- Transcriptome-wide Association of Mki67 Expression: Pre- And Post-neoadjuvant PaclitaxelMoyer AM, Kalari KR, Thompson KJ, Visscher DW, Suman VJ, Eckel-Passow J, Sicotte H, Hart SN, Sinnwell JP, Dockter TJ, Jones KN, Conners AL, Tang X, Yu J, Gao B, Mahone..., Mod Pathol, 1/1/2014
- Phase I Dose-escalation And Drug Interaction Study Of Abt-888 (parp1 Inhibitor) And Topotecan (topoisomerase I Inhibitor) In Patients With Advanced CancerBoakye-Agyeman F, Reid J, Menefee M, Buhrow S, Walden C, Piens J, Kayode O, Erlichman C, Haluska P,Northfelt DW, Kaufmann SH, Ames M, Satele DV, Tang H, Peethambaram P..., Clin Pharmacol Ther, 1/1/2014
- Join now to see all
Lectures
- Interesting Cases in Breast DiseaseScottsdale, Arizona - 1/1/2013
- What Should I Eat, How Should I Exercise, How Can I Lose Weight?Scottsdale, Arizona - 1/1/2012
- What's New in Breast, Lung, Prostate, and Colon Cancer for the Primary PhysicianSedona, Arizona - 1/1/2012
- Join now to see all
Press Mentions
- Breast Cancer Clinical Trails: Why They Are ImportantJune 3rd, 2022
- Breast Cancer Now Leading Cause of Cancer Death in African American/Black WomenFebruary 11th, 2022
- Meet Heidi Kosiorek, Biostatistician and Cancer ResearcherApril 29th, 2020
- Join now to see all
Professional Memberships
- Member
- Fellow
- Member
Hospital Affiliations
- U. S. Public Health Service Phoenix Indian Medical CenterPhoenix, Arizona
- Mayo Clinic HospitalPhoenix, Arizona
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: